Skip to content

Author

R. Aly

We have 2 of 47 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Osimertinib, platinum, and etoposide for patients with metastatic EGFR/TP53/RB1-mutant lung cancers at risk for histological transformation.

Although EGFR inhibitors are highly effective for treating EGFR-mutant lung adenocarcinomas (EGFR+ LUADs), resistance inevitably emerges, with histologic transformation to small cell lung cancer (SCLC) representing a particularly aggressive mechanism. Our prospective trial enrolled patients with EGFR+ LUAD at high risk...

L. Morrill Gavarró, Monica F. Chen, Á. Quintanal-Villalonga et al. · 0 citations
Sep 2026

Grade 3 Lung Carcinoids/NETs: The IASLC Pathology Committee Study with Proposal of a New Diagnostic Category.

INTRODUCTION Lung carcinoids are well-differentiated neuroendocrine tumors (NETs), designated in the current thoracic WHO classification as typical carcinoids (grade 1) and atypical carcinoids (grade 2), whereas rare tumors with carcinoid/NET morphology and >10 mitoses/2mm2 are designated as large cell neuroendocrine c...

N. Rekhtman, Matthew G. Hanna, Paul Hofman et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.